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Background and purpose: Mean platelet volume (MPV), an indicator of platelet activation, has
been shown to be elevated in patients with coronary artery disease (CAD) in some studies.
Insulin resistance contributes to increased platelet activation and it is one of the risk factors
for CAD. The aim of this study was to assess the relationship between insulin resistance and
MPV in non-obese, non-diabetic patients with CAD.
Methods and subjects: Seventy-seven non-obese, non-diabetic CAD patients were divided into
two groups, insulin resistant and insulin sensitive according to the homeostasis model assess-
ment insulin resistance index (HOMA-IR). The insulin-resistant group was composed of 45
patients (30 males/15 females; mean age 59.8± 11.1 years). The insulin-sensitive group was
composed of 32 patients (17 males/15 females; mean age 58.9± 12.2 years).
Results: Insulin and HOMA-IR values were signiﬁcantly higher in insulin-resistant CAD patients
than in insulin-sensitive CAD patients. The MPV values were signiﬁcantly higher in insulin-
resistant CAD patients than in insulin-sensitive CAD patients (8.6± 1.0 ﬂ vs. 8.0± 0.7 ﬂ;
respectively, p = 0.01). The MPV was poorly correlated with HOMA-IR (r = 0.30, p = 0.054) and
insulin (r = 0.22, p = 0.053).
Conclusions: We have shown that MPV was signiﬁcantly elevated in insulin-resistant non-obese,
non-diabetic CAD patients when compared to insulin-sensitive non-obese, non-diabetic CAD
patients.
© 2010 Japanese College of Car
∗ Corresponding author at: Süleyman Demirel Univesitesi Tıp
akültesi, Sevket Demirel Kalp Merkezi, Isparta, Turkey.
el.: +90 5323468258; fax: +90 2462324510.




914-5087/$ — see front matter © 2010 Japanese College of Cardiology.
oi:10.1016/j.jjcc.2010.03.005diology. Published by Elsevier Ireland Ltd. All rights reserved.ntroduction
nsulin resistance is established to be one of the risk fac-
ors for coronary artery disease (CAD) [1]. Insulin resistance


















































fMean platelet volume is associated with insulin resistance in
underlies the metabolic syndrome that includes central obe-
sity, dyslipidemia, hyperglycemia, hypertension, impaired
ﬁbrinolysis, and atherosclerosis [1,2].
Recent studies showed that insulin resistance contributes
to increased platelet activation in obesity [3—5].
Mean platelet volume (MPV), an indicator of platelet
activation has an important role in the pathophysiology of
cardiovascular diseases [6,7]. MPV is an important biological
variable and larger platelets have higher thrombotic poten-
tial [8]. In comparison to smaller ones, larger platelets have
more granules, aggregate more rapidly with collagen, have
higher thromboxane A2 levels, and express more glycopro-
tein Ib and IIb/IIIa receptors [9—11].
Elevations of MPV values have been shown in patients
with CAD [12,13]. Elevations of MPV values have also been
shown in conditions that are closely related to insulin resis-
tance such as metabolic syndrome, obesity, impaired fasting
glucose, diabetes mellitus, and hypertension [14—17]. These
conditions are also risk factors for CAD. To the best of our
knowledge, no study has investigated speciﬁcally the direct
relationship between insulin resistance and MPV in patients
with CAD. Accordingly, the aim of our study was to eval-
uate the relationship between insulin resistance and MPV
in patients with CAD. Diabetes mellitus and obesity cause
an increase in platelet size [14—16]. To overcome this dif-
ﬁculty, we performed this study in non-obese, non-diabetic
CAD patients.
Patients and methods
We studied 77 consecutive non-obese, non-diabetic patients
(47 males/30 females; mean age 59.4± 11.5 years) with
CAD. All patients underwent coronary angiography. The indi-
cation for coronary angiography was either the presence
of typical angina or positive or equivocal results of nonin-
vasive screening tests for myocardial ischemia in both of
the groups. Patients were divided into two groups, insulin
resistant and insulin sensitive according to the homeosta-
sis model assessment insulin resistance index (HOMA-IR).
The insulin-resistant group was composed of 45 patients
(30 males/15 females; mean age 59.8± 11.1 years). The
insulin-sensitive group was composed of 32 patients (17
males/15 females; mean age 58.9± 12.2 years). Hyperten-
sion was considered to be present if the systolic pressure
was >140mmHg and/or diastolic pressure was >90mmHg,
or if the individual was taking antihypertensive medications.
Diabetes mellitus was deﬁned as plasma fasting glucose
≥126mg/dl and/or the current use of diabetes medication.
Obesity was deﬁned as body mass index ≥30 kg/m2. Patients
who were smoking before hospitalization were classiﬁed as
smokers. Exclusion criteria were prior to myocardial infarc-
tion, valvular heart disease, heart failure, diabetes mellitus,
peripheral vascular disease, renal and hepatic dysfunction,
hematological disorders, history of malignancy, acute or
chronic infection, and stroke. All patients gave informed
consent and the study was approved by the institutional
ethics committee.Coronary angiography
Coronary angiography was routinely performed without the
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erformed by means of the Judkins technique in multiple
rojections. We used iohexol (Omnipaque, GE Healthcare,
rinceton, NJ, USA) as contrast agent during coronary
ngiography in all patients and control subjects. Coronary
ngiograms were analyzed by two blinded interventional
ardiologists without knowledge of the clinical status and
aboratory measurements of the subjects. CAD was deﬁned
s >50% stenosis in major epicardial vessels.
iochemical measurements
lood samples were drawn from the antecubital vein by
areful vein puncture in a 21G sterile syringe without stasis
t 08:00—10:00 a.m. after a fasting period of 12 h. Glucose,
reatinine, lipid proﬁles, and insulin levels were determined
y standard methods. MPV was measured in a blood sam-
le collected in dipotassium EDTA tubes within 30min to
revent EDTA-induced swelling. An automatic blood counter
Beckman Coulter, Fullerton, CA, USA) was used for whole
lood counts. The estimate of insulin resistance by home-
stasis model assessment (HOMA-IR) was calculated with the
ormula: fasting serum insulin (mIU/l)× fasting plasma glu-
ose (mmol/l)/22.5 [18]. Insulin resistance (HOMA-IR) was
eﬁned as an index >2.245, a cut-off that represented the
0th percentile in non-diabetic adults in the Turkish Adult
isk Factor Study [19].
tatistical analysis
ata were analyzed with the SPSS software version 10.0 for
indows (SPSS Inc., Chicago, IL, USA). Continuous variables
rom the study groups were reported as mean± standard
eviation, categorical variables as percentages. To compare
ontinuous variables, the Student’s t-test or Mann—Whitney
-test were used where appropriate. Categorical variables
ere compared with the chi-squared test. Statistical signif-
cance was deﬁned as p < 0.05. Pearson correlation analysis
as used to assess the association between MPV and HOMA-
R, insulin, and other laboratory parameters.
esults
he clinical and laboratory characteristics of the insulin-
esistant and insulin-sensitive patients with CAD are
resented in Table 1. There were no statistically signif-
cant differences between the two groups with respect
o age, gender, smoking habit, levels of glucose, creati-
ine, total cholesterol, triglyceride, low-density lipoprotein
LDL) cholesterol, or high-density lipoprotein (HDL) choles-
erol. Insulin and HOMA-IR values were signiﬁcantly higher
n insulin-resistant CAD patients than in insulin-sensitive
AD patients. The hematological parameters of the insulin-
esistant and insulin-sensitive patients with CAD are shown
n Table 2. There were no statistically signiﬁcant dif-
erences between the two groups with respect to levels
f white blood cells (WBC) and hemoglobin. The MPV
alues were signiﬁcantly higher in insulin-resistant CAD
atients than in insulin-sensitive CAD patients (8.6± 1.0 ﬂ
s. 8.0± 0.7 ﬂ; respectively, p = 0.01). The platelet count
as signiﬁcantly lower in insulin-resistant CAD patients
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Table 1 Comparison of the clinical and laboratory characteristics of the insulin-resistant and insulin-sensitive patients with
coronary artery disease.
Insulin resistant (n = 45) Insulin sensitive (n = 32) p-Value
Age (years) 59.8± 11.1 58.9± 12.2 0.74
Sex (M/F) 30/15 17/15 0.24
BMI (kg/m2) 27.2± 3.8 25.9± 2.8 0.10
SBP (mmHg 120.7± 12.5 116.4± 11.7 0.16
DBP (mmHg) 76.2± 8.3 73.8± 8.2 0.20
Smoking (%) 9 (28%) 17 (37%) 0.46
HOMA-IR 3.8± 1.3 1.3± 0.4 <0.001
Insulin (mIU/l) 9.0± 2.9 3.3± 1.1 <0.001
Glucose (mg/dl) 95.1± 5.3 92.7± 6.2 0.07
Creatinine (mg/dl) 1.0± 0.2 0.9± 0.2 0.14
Total cholesterol (mg/dl) 186.8± 46.5 198.5± 62.7 0.34
Triglycerides (mg/dl) 173.5± 81.7 150.5± 74.1 0.21
LDL-cholesterol (mg/dl) 108.0± 39.2 122.4± 56.80.19
HDL-cholesterol (mg/dl) 44.0± 8.8 46.7± 13.1 0.29
Medications
Beta blockers 16 (35%) 12 (37%) 0.86
ACE inhibitors 12 (26%) 7 (22%) 0.63
Ca channel blockers 11 (24%) 8 (25%) 0.95
ASA 41 (91%) 28 (87%) 0.60
Statin 30 (66%) 20 (62%) 0.70
M/F, male/female; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model
assessment insulin resistance index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE, angiotensin-converting enzyme;
ASA, aspirin; p-value is for comparison between control and study population.
Table 2 Comparison of the hematological parameters of the insulin-resistant and insulin-sensitive patients with coronary artery
disease.
Insulin resistant (n = 45) Insulin sensitive (n = 32) p-Value
WBC (×103 mg/dl) 7.7 ± 2.2 7.6 ± 2.9 0.78
Hemoglobin (g/dl) 14.8 ± 1.2 14.3 ± 1.3 0.09































iMPV (ﬂ) 8.6 ± 1.0
WBC, white blood cell; MPV, mean platelet volume. p-Value is for
han in insulin-sensitive CAD patients (226.7± 60.0 vs.
60.9± 63.3; respectively, p = 0.02). The MPV was poorly
orrelated with HOMA-IR (r = 0.30, p = 0.054) and insulin
r = 0.22, p = 0.053).
iscussion
n the present study, we investigated the relationship
etween insulin resistance and MPV in non-obese, non-
iabetic patients with CAD. We found that MPV, an indicator
f platelet activation was higher in insulin-resistant CAD
atients than in insulin-sensitive CAD patients.
It is known that increased platelet activation and aggre-
ation are closely related to cardiovascular complications
7]. The determination of platelet size, usually via quantiﬁ-
ation of MPV, is a simple and easy method of accurately
ssessing platelet function. Platelets are heterogeneous in
ize, density, and reactivity. Larger platelets have a greater





p8.0 ± 0.7 0.01
parison between control and study population.
ctive than smaller platelets. In comparison to smaller ones,
arger platelets have more granules, aggregate more rapidly
ith collagen, have higher thromboxane A2 levels, and
xpress more glycoprotein Ib and IIb/IIIa receptors [9—11].
It has been reported that elevated values of MPV were
ssociated with cardiovascular diseases [12,13]. However,
he association of MPV with insulin resistance, which has
een accepted as one of the risk factors for CAD, has
ained little attention. Tavil et al. showed that patients
ith metabolic syndrome had higher MPV compared to con-
rol subjects with normal coronary angiograms. To evaluate
he severity of coronary artery disease, they subdivided
he patients with metabolic syndrome depending upon the
oexistence of CAD: normal coronary arteries (group 1); hav-
ng coronary stenotic lesions of <50% (group 2); and having
oronary stenotic lesions of >50% (group 3). There was no
tatistically signiﬁcant difference in MPV values among the
roups with respect to CAD severity. They also found that
etabolic syndrome patients with CAD had higher MPV com-
























[Mean platelet volume is associated with insulin resistance in
However, they did not measure insulin resistance in patients
with metabolic syndrome and its association with MPV and
CAD. In our study we investigated the direct relationship
between insulin resistance and MPV in patients with CAD.
Muscari et al. reported that, in an unselected population
of elderly subjects, percent body fat, blood glucose, and
ischemic electrocardiographic changes were found to be the
main determinants of MPV, and MPV tended to be higher
in subjects with higher HOMA index (p = 0.09) [20]. How-
ever, they did not perform coronary angiography in study
patients especially in those having ischemic electrocardio-
graphic changes. We selected all patients from individuals
who underwent coronary angiography with suspicion of CAD.
In an another study about the relationship between MPV and
insulin resistance, Yazici et al. found signiﬁcantly higher
baseline MPV values in prehypertension subjects than in
those with an optimal blood pressure and they found that
MPV showed a modestly positive correlation with the insulin
resistance index using HOMA in prehypertension subjects
[21]. Additionally, MPV values were signiﬁcantly higher in
patients with insulin resistance than in patients without
insulin resistance in this study. After lifestyle modiﬁcation,
MPV and HOMA-IR values were signiﬁcantly reduced in the
prehypertension group. They suggested that reduction of
insulin resistance may play a modest role in the decrease
in MPV in this speciﬁc group of patients.
A few studies have demonstrated a strong associa-
tion between insulin resistance measured directly and CAD
[2,22—25]. On the other hand, hyperinsulinemia has also
been related to CAD [26,27]. Insulin is associated with a
functional change in platelets that promotes thrombosis
[5]. Human platelets have insulin receptors that partici-
pate in the regulation of platelet functions [28]. In vitro
and in vivo studies have demonstrated that insulin inhibits
platelet aggregation and activation in insulin-sensitive sub-
jects [5,29]. In conditions of insulin resistance, a reduction
in platelet sensitivity to the antiaggregating effects of
insulin has been reported [5,29,30].
One of the other possible mechanisms is the increased
platelet reactivity due to the direct effect of hyperglycemia
via osmotic effects on platelets [31]. Another mechanism
potentially contributing to increased platelet reactivity is
vascular dysfunction. Decreased vascular endothelial pro-
duction of prostacyclin and nitric oxide in patients with
insulin resistance promotes increased activation of platelets
[32].
Insulin resistance, diabetes mellitus, and other risk fac-
tors associated with endothelial dysfunction might trigger
the series of cytokine production [32]. The cytokines pro-
duced by adipose tissue and the dysfunctioning endothelium
may stimulate the production of large platelets in the bone
marrow [33]. Platelet size is regulated at the level of the
megakaryocyte. Researchers have reported that cytokines
such as interleukin-3 or interleukin-6 inﬂuence megakary-
ocyte ploidy and can lead to the production of more reactive
and larger platelets [34—36].
Recently, Deveci et al. showed that insulin resistance
is present in normoglycemic patients with CAD and HOMA-
IR may be a more sensitive method than the deﬁnitions
of metabolic syndrome for the evaluation of the relation-
ship between insulin resistance and CAD in normoglycemic
patients [37]. Our study population was also composed
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f non-obese, normoglycemic patients with CAD and we
ssessed the relationship between MPV and insulin resis-
ance in this group of patients. We speculated that there
ight be close relationship between insulin resistance and
PV, an indicator of platelet activation, in patients with
on-obese, non-diabetic patients with CAD.
The small number of patients was the ﬁrst limitation of
he study. The second limitation of this study was that anal-
sis was based on a simple baseline determination that may
ot reﬂect the patient status over long periods. As a third
imitation, although we selected normoglycemic patients
nd excluded diabetes mellitus, we did not perform oral glu-
ose tolerance test to exclude impaired glucose tolerance.
onclusion
n this study, we have shown that MPV was signiﬁcantly
igher in insulin-resistant CAD patients than insulin-sensitive
AD patients. To overcome insulin resistance in CAD,
atients could decrease the platelet activation and conse-
uently morbidity and mortality. Further prospective studies
re mandatory to establish the relationship between insulin
esistance and platelet volume in CAD patients.
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